Gyre Therapeutics (GYRE) Total Non-Current Liabilities (2016 - 2025)
Historic Total Non-Current Liabilities for Gyre Therapeutics (GYRE) over the last 9 years, with Q3 2025 value amounting to $18.7 million.
- Gyre Therapeutics' Total Non-Current Liabilities rose 1712.7% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 1712.7%. This contributed to the annual value of $16.4 million for FY2024, which is 2015.31% down from last year.
- Per Gyre Therapeutics' latest filing, its Total Non-Current Liabilities stood at $18.7 million for Q3 2025, which was up 1712.7% from $20.0 million recorded in Q2 2025.
- Over the past 5 years, Gyre Therapeutics' Total Non-Current Liabilities peaked at $22.1 million during Q1 2025, and registered a low of $1.8 million during Q3 2023.
- Over the past 4 years, Gyre Therapeutics' median Total Non-Current Liabilities value was $16.7 million (recorded in 2024), while the average stood at $14.1 million.
- Over the last 5 years, Gyre Therapeutics' Total Non-Current Liabilities had its largest YoY gain of 97982.65% in 2024, and its largest YoY loss of 2015.31% in 2024.
- Quarter analysis of 4 years shows Gyre Therapeutics' Total Non-Current Liabilities stood at $12.5 million in 2022, then skyrocketed by 64.31% to $20.5 million in 2023, then dropped by 20.15% to $16.4 million in 2024, then rose by 14.47% to $18.7 million in 2025.
- Its Total Non-Current Liabilities was $18.7 million in Q3 2025, compared to $20.0 million in Q2 2025 and $22.1 million in Q1 2025.